Introduction
============

Botswana is one of the countries hardest hit with the HIV pandemic \[[@R1]\]. To respond to this public health menace, the Government of Botswana launched its national antiretroviral therapy (ART) programme called 'Masa', meaning 'new dawn' in Setswana. By the end of 2014, the programme had expanded to more than 302 healthcare facilities, and eligibility requirements had increased the CD4^+^ threshold to 350 cells/μl. By December 2014, the number of patients ever initiated ART had reached 247 856, of which 229 133 were in the public sector \[[@R2]\].

Prior studies have shown the success of this programme in Botswana \[[@R3],[@R4]\]. However, these studies were hampered by small sample sizes. An analysis of the routinely collected patient data is needed to evaluate the performance of the national programme over time.

This study builds on our prior work \[[@R5]\], by providing a rigorous evaluation of 12 years of follow-up data for adult patients in the Masa Programme. This analysis was designed to evaluate rates of mortality, while identifying potential risk factors for mortality, including clinical and demographic factors.

Methods
=======

Data
----

We analysed a database of all available electronic records routinely collected for 226 030 HIV-infected adults from 176 healthcare facilities enrolled in the Masa Programme with a documented ART initiation date. Once eligible for ART, data are collected through a patient information management system (PIMS) developed by the Ministry of Health (MOH) in Microsoft Access, or in nine major hospitals and 12 clinics, through a commercial information system. All available databases were integrated in a Microsoft SQL database in the data warehouse at the MOH. Despite the fact that all hospitals and most clinics had an electronic information system by the end of 2012, data are not always routinely entered and reported consistently for all facilities due to inadequate resources.

During the data cleaning process, we removed 620 individuals' observations for having clinical records over 90 days after documented death. Because some clinics keep ART drug refill records separately to PIMS, the drug regimens from 68 facilities were not available for this analysis. The individuals without documented antiretroviral regimens or no baseline CD4^+^ cell counts dropped from regression models, which restricted the sample to 94 166 (see Fig. [1](#F1){ref-type="fig"}). Observations from 86 845 were included in a sensitivity analysis where individuals initiated in 2012 and 2013 are removed from the original model. These individuals were excluded because they might have had a different pattern of mortality and loss to follow-up (LTFU) than those who initiated earlier \[[@R6]\].
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The primary outcome measure for this analysis was mortality. For this analysis, 'documented death' referred to a death event recorded in the database. Some deaths were not reported to the Masa Programme, leading those individuals to be marked as LTFU. LTFU here is defined by no recorded clinical visits or prescription refills for 90 days after a missed clinical visit/refill. Baseline CD4^+^ cell counts were defined as any CD4^+^ cell count reported in the 90 days before treatment initiation, only if there was not a recorded baseline CD4^+^ cell count.

Statistical analysis
--------------------

We used a person-years (P-Y) approach to analyse event rates. Follow-up time was measured from the date of ART initiation until death, or to the date of the last visit to the clinic. For the patients who did not start ART immediately after enrolment, only their post-ART follow-up time entered the analysis.

We used marginal structural modelling to estimate predictors of death among HIV patients on ART. We used this technique to address the complex issue of LTFU and prevent bias in interpreting the results \[[@R7],[@R8]\]. Using observed variables, this approach allows us to derive a weight for each individual in each quarter, i.e., the inverse probability of remaining in the study in that interval \[[@R9]\]. Following the literature, the stabilized version of inverse probability of LTFU was estimated as a ratio of two predicted probability from two pooled logistic regression models. To correct for auto-correlation in the panel setting, we clustered the standard errors at patient level; and to deal with the clustering effect at district-level, we included dummy variable for each district in the models as fixed effect. In the model for the numerator only the baseline covariates were included, while for the denominator the logistic model was fitted with the baseline and time-varying covariates \[[@R10]\].

In the regression model we used all the patient-level demographic and medical variables captured for the majority of the patients in the database. The variables include age, sex, CD4^+^ cell count, and treatment regimen at baseline. We did not include viral load data due to poor data quality. Additionally, treatment initiation calendar year was included to capture the potential effect of guideline changes. Medication regimen at each quarter was added as the time-varying variable.

To evaluate the robustness of the findings, we performed a sensitivity analysis by removal of the observations from the last 2 years (2012 and 2013) due to low numbers of observations and documented deaths, and the potential of these patients to have different patterns of mortality and LTFU. We also restricted the model to patients who had only been on treatment for less than a year, to see how these patients may differ from the overall model results.

Results
=======

In the database used for this analysis, the number of patients ever initiated ART in the Masa Programme increased from 3206 in 2002 to 226 030 by October 2013 \[These are the numbers of enrollees in the programme whose records were captured electronically and after data cleaning to remove observations with poor data quality\]. The largest increase in initiation was in 2006, after which the increasing rate of ART initiation gradually declined.

Table [1](#T1){ref-type="table"} contains descriptive statistics for the patients in the Masa programme. Of these patients, 82% had a baseline CD4^+^ cell count value in the database. A high percentage of the study population was female (62%), and median age at baseline was 33 for women \[interquartile range (IQR) 28--40\] and 38 for men (IQR 32--45).

The median baseline CD4^+^ cell count was 147 cells/μl (IQR 79--200). Majority of the patients (72%) have a CD4^+^ cell count between 50 and 250 cells/μl, whereas 15% of patients initiated with a very low baseline CD4^+^ cell count (\<50 cells/μl). As a result of changing the CD4^+^ cell count threshold for ART eligibility from 200 to 250 cells/μl in 2008, 18 777 patients with CD4^+^ cell count between 200 and 250 cells/μl were able to start treatment earlier. Median baseline CD4^+^ cell count increased from 88 cells/μl (IQR 38--156) in 2002, to 258 cells/μl (IQR 147--337) in 2013.

A total of 15 150 (7%) patients died during 2002--2013, of whom 9670 (64% of total deaths) died in the first year after treatment initiation, of those who died in the first year, 6261 (65% of deaths in the first year) died in the first 3 months. We found that the proportion of deaths in the first week, first 3 months, and first year of treatment have been decreasing over the 12 years of the Masa Programme (see Fig. [2](#F2){ref-type="fig"}). In 2002, 229 people (7%) initiating ART died in their first year of treatment, whereas in 2012, 340 people (2%) initiating ART died in their first year.
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The average mortality rate was 2.06 deaths per 100 P-Y over a total follow-up time of 687 759 P-Y. Mortality rate was greatest in the first year of follow-up at 5.30 deaths per 100 P-Y \[95% confidence interval (CI) 5.19--5.41\] and decreased to 1.01 deaths per 100 P-Y (95% CI 0.98--1.04), after the first year on ART. Within the first year of treatment, the first 3 months shows highest mortality rate at 11.79 deaths per 100 P-Y (95% CI 11.49--12.11), but the rate decreases to 1.88 deaths per 100 P-Y (95% CI 1.75--2.03) between 9 and 12 months after treatment initiation. Moreover, the rate during the first 3 months on ART decreased over the years of the programme. The mortality rate in the first 3 months of treatment was 14.29 deaths per 100 P-Y (95% CI 13.41--15.23) in 2005 and decreases over time to 6.34 deaths per 100 P-Y (95% CI 5.57--7.22) in 2012 (see Fig. [3](#F3){ref-type="fig"}).
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Median follow-up time was 37 months (IQR 11--75). The median duration of follow-up for patients who were LTFU was 24 months (IQR 8--47), compared with a median of 52 months (IQR 16--89) for those who were not lost. The incidence of LTFU was 12.47 per 100 P-Y (95% CI 12.38--12.55) overall. However, LTFU rate was 14.87 per 100 P-Y (95% CI 14.68--15.05) for patients in their first year of ART treatment, with the lowest rate between 3 and 6 months \[13.33 per 100 P-Y (95% CI 12.98--13.69)\], and highest between 9 and 12 months \[18.18 per 100 P-Y (95% CI 17.75--18.61)\]. The lowest rate of LTFU by year of initiation was 7.74 per 100 P-Y (95% CI 7.52--7.97) in 2003, and the highest rate of LTFU was 22.45 per 100 P-Y (95% CI 21.75--23.18) for those initiating in 2011. Some patients who were transferred were considered LTFU, as there was not enough data to match their records across facilities. There were 51 548 patients who transferred facilities since 2002, and only 14 922 of transferred patients had their records linked.

For 128 450 patients whose first-line ART medication was available and consistent in the Masa Programme database \[Some of the ART drug data was removed because of inconsistency, e.g. if the medical records indicated that a patient was on tenofovir and zidovudine at the same time.\], zidovudine and tenofovir were the main nucleoside/nucleotide reverse-transcriptase inhibitors (NRTIs) used, with 72% of people starting with zidovudine compared with 21% on tenofovir \[Following the 2008 change in the guideline, tenofovir replaced zidovudine as the first-line NRTI in Botswana.\] and the remainder of patients, 7%, on stavudine. Since almost all patients who started on zidovudine also received lamivudine, and those who started on tenofovir also receive emtricitabine either separately or as a combination, Combivir and Truvada (or Atripla), respectively, we just mention zidovudine and tenofovir throughout this article. The population on non-nucleoside reverse-transcriptase inhibitors (NNRTIs) were split between efavirenz and nevirapine, 57 and 41%, respectively, with the remainder of patients, 2%, starting on the protease inhibitor (PI), lopinavir.

Regression analysis
-------------------

Table [2](#T2){ref-type="table"} presents the results of the marginal structural model (weighted to compensate for the patients LTFU), an analysis of patients in their first year of treatment and the sensitivity analysis. Comparing three main first-line NRTI medications in Botswana National ART Programme, namely zidovudine, tenofovir and stavudine, we found that the mortality odds ratio among patients starting on zidovudine was 1.2 times that of tenofovir (95% CI 1.1--1.3). Stavudine-containing regimens were associated with 4.9 times the odds of mortality rate compared with tenofovir (95% CI 4.3--5.6). Those on efavirenz had a slightly higher rate of mortality when compared with those on nevirapine with an odds ratio (OR) of 1.12 (95% CI 1.03--1.2). The odds of mortality for those who switched NRTI or NNRTI are less, as compared with those who stayed with the original prescription.

Those who initiated ART after 2008 had lower odds of mortality compared with those who initiated before 2008. Our model predicted a lower risk of mortality for women \[OR 0.64, (95% CI 0.60--0.69)\], compared with men. The odds of death increased after the age of 40. Additionally, having a baseline CD4^+^ cell count below 100 increased the odds of death by 1.89 times (95% CI 1.79--1.99).

Model 2, including only those that have been on treatment for less than a year, shows similar results to the main model with a few key differences. The odds of mortality with zidovudine and stavudine was higher compared with tenofovir, whereas patients on efavirenz were less likely to die compared with those on nevirapine \[OR 0.87 (95% CI 0.79--0.97)\]. Having a baseline CD4^+^ cell count of less than 100 cells/μl has a stronger effect in this model than in the model containing all individuals \[OR 2.56 (95% CI 2.37--2.77)\]. In Model 3, only one estimate changed after removing those initiating in the last 2 years, specifically the inferiority of zidovudine became statistically insignificant.

Discussion
==========

This study is the first comprehensive analysis of the trends and determinants of mortality for over 200 000 patients in an African National ART Programme. We found low rate of mortality and high rate of LTFU after treatment initiation, which was similar to other African cohorts \[[@R11]\]. The crude mortality rate was 2.06 deaths per 100 P-Y, which is lower than a Ghanaian cohort, with 2.9 deaths per 100 P-Y \[[@R12]\], and a Rwandan cohort with 3.7 deaths per 100 P-Y \[[@R13]\], and higher than a similar cohort in South Africa, with 1.08 deaths per 100 P-Y \[[@R14]\]. All of these estimates are substantially lower than the 16.1 deaths per 100 P-Y found in a Zambian cohort \[[@R15]\].

In this study, like similar studies in sub-Saharan Africa \[[@R16]\], more than 64% of deaths happened in the first year after treatment initiation. However, the percentage of individuals who died in their first year of treatment has been steadily decreasing over the years, from 7 to 2% of those initiating ART during 2002--2012. Our findings are similar to a study evaluating seven programmes in South Africa, where 12-month mortality decreased to 6% in 2007 from 9% in 2002 \[[@R17]\]. This suggests that patients are now remaining in the programme longer, and can be successfully treated, although early mortality is still a major concern.

Crude mortality rate in the first 3 months of ART initiation is at 11.8 deaths per 100 P-Y, which is significantly lower than estimates found in other studies. In a South African cohort, followed from 2007 to 2012, the crude mortality rate in the first 3 months of ART was 19.4 per 100 P-Y. The mortality rate during the first 3 months of treatment in Zambia and China was found to be 26 and 22.6 deaths per 100 P-Y respectively \[[@R15],[@R18]\]. Differences in follow-up period and a significant drop in mortality rates across the 12 years of the programme may explain the differences in these estimates.

A notable outcome of the rapid scaling-up of the Botswana National ART programme from 2002 to 2013 was its success in decreasing mortality in the first 3 months after treatment initiation from more than 20 deaths per 100 P-Y in 2002, to six deaths per 100 P-Y in 2012. A similar pattern, but higher rates are found in a study in South Africa, where mortality rates in the first 3 months dropped from 21.4 per 100 P-Y (95% CI 18.3--24.8) in 2004--2005 to 9.0 per 100 P-Y (95% CI 7.3--11.0) in 2011--2012 \[[@R19]\]. It is likely that the high rates of LTFU in the third and fourth quarter after ART initiation in Botswana are causing us to underestimate mortality rates 6 months after ART initiation. Although this trend is often seen in similar studies in resource-limited settings, the mortality rates in Botswana remain a great deal lower, even when mortality rates are restricted to the same years of follow-up \[[@R15],[@R18]\]. Diminishing rate of mortality in the first 3 months after treatment initiation in Botswana can be partially explained by higher CD4^+^ cell counts at treatment initiation and by replacing zidovudine with tenofovir as the first-line regimen in 2008 \[[@R20]\].

Some patients in our study may fulfil the definition of LTFU because they were transferred, but their medical records could not be linked due to differences in patient identifiers or differences in reporting consistency at the receiving facility. Some patients may have died without being recorded in the electronic system. Using a method to trace patients, a study of 524 patients in Botswana in early 2003 showed that more than half of the 68 patients originally deemed to be LTFU were confirmed to be dead after tracing. Therefore, many of the patients who are LTFU in our study have probably died \[[@R21]\].

Some of the LTFU can be explained by poor data quality. Some LTFU patients were probably still receiving care, but the facility failed to fill in the medical record electronically. Some facilities reported only demographic data and failed to report the laboratory results or prescription drug regimens of patients. Even the data reporting quality, or lack thereof, at certain facilities was not consistent, and fluctuated over time. Improving the data collection process should be a priority in the Masa Programme.

Although average retention across districts in Botswana has improved over time, many patients did not receive medical care at recommended intervals. Retention in care for those on ART is essential as they need to ensure uninterrupted receipt of ART, prevention and treatment of opportunistic infections, as well as continued clinical and laboratory monitoring to detect drug-related toxicity or treatment failure \[[@R22]\].

In this analysis, tenofovir was found to be associated with substantially lower rate of mortality compared with zidovudine and stavudine, which have higher rates of toxicity \[[@R23]\]. Our findings are in line with the results of other studies in the literature. In randomized trials, tenofovir has demonstrated comparable or greater efficacy compared with other first-line regimens, such as zidovudine and stavudine \[[@R24]\].

The results presented show that efavirenz was slightly inferior to nevirapine. In the sensitivity analysis, the result was reversed, which may confirm the findings of previous studies concluding there was no difference in efficacy between the two drugs \[[@R25]\]. Although we are not able to offer an explanation for the inferiority of efavirenz in the main model, we can stipulate that there were unmeasured confounders associated with prescription of NNRTIs in Botswana that contributed to inferior outcomes for efavirenz in this study.

Being highly immunosuppressed at the initiation of therapy, with a baseline CD4^+^ cell count less than 100 cells/μl, was a strong predictor of mortality, as has been shown in several similar studies \[[@R26],[@R27]\]. Consistent with the literature, higher CD4^+^ levels in this population were positively correlated with survival.

Consistent with similar studies \[[@R15],[@R28]\], individuals who were male and older individuals were more likely to die in the Masa Programme. There is a range of explanations for gender difference in mortality on ART. Given that in our regression model we accounted for the baseline CD4^+^ level and duration of follow-up, one probable explanation for lower mortality among women would be superior adherence to ART, which we could not control for in our model. In Botswana, like other studies in similar settings, women\'s better outcome can be associated with better treatment adherence and health-seeking behaviour \[[@R29]--[@R31]\]. Moreover, the cause of death in the database is unknown, and some of these patients may have died of non-AIDS defining conditions \[[@R32]\]. There is higher mortality among men in general as men are more likely to have risk factors for respiratory and cardiovascular disease, and to be involved in motor vehicle accidents, homicide, and suicide \[[@R33]\]. It is also important to note that older individuals are more likely to die from other causes unrelated to AIDS, e.g., cardiovascular disorders, cerebrovascular accidents, and cancer, which may contribute to higher mortality in this age. Therefore, we cannot necessarily establish a correlation between the HIV infection or treatment status and higher mortality rate among the male or older patients.

Limitations
-----------

There are limitations to this study that should be acknowledged. The main limitation is the potential for missing death data due to inconsistent reporting; however; we tried to account for this through our analysis of patients lost to follow-up, specifically in the regression model, by using marginal structural modelling to correct for bias that it may have introduced. There is also missing data for ART regimen and CD4^+^; however, it is less troubling as causes of missing data may include understaffing, lack of adequate training, and poor data recording due to lack of infrastructure. We could not find any evidence indicating missing data and incorrect entries may have introduced selection bias to this analysis, or have limited the generalizability of these findings, unless a correlation between documentation and quality of care is assumed. Strengths of this study include our large sample size and repeated measures over 12 years of the Masa Programme.

Conclusions
-----------

Our analysis of the Botswana National ART Programme highlights areas of success and areas needing improvement. The success of the programme can be explained, in part, by the fact that the system adjusted itself through revising the treatment guidelines, earlier identification of the patients in the course of their infection, better trained personnel and an improved health information system \[[@R5]\]. The programme succeeded in reducing overall as well as early mortality (12 months and 3 months after treatment initiation). Although earlier HIV diagnosis and ART initiation at higher CD4 can improve survival, the findings of this study call for interventions to target reduction in early mortality and in keeping patients engaged in care. Last but not least, the study emphasizes the critical role of high-quality, routine data collection and reporting, for epidemiological studies and day-to-day clinical practice.
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###### 

Baseline patient characteristics for patients^a^ initiating antiretroviral treatment in the Botswana National HIV/AIDS Treatment Programme, 2002--2013.

  Continuous variables                   Median            IQR                      Total
  -------------------------------------- ----------------- ------------------------ ---------
  Number of clinic visits                5                 2--10                    226 030
  Months of follow-up                    37                11--75                   202 818
  Age (years)                            35                29--42                   214 804
  Baseline CD4^+^                        147               79--200                  185 805
  Indicator variables                    No. of patients   \% of study population   
  Women                                  138 653           61.8                     224 310
  Year of initiation                                                                226 030
   2002--2007                            121 509           53.8                     
   2008--2013                            104 521           46.2                     
  First-line ART regimen (NNRTI or PI)                                              128 450
   Nevirapine                            52 346            40.8                     
   Efavirenz                             73 655            57.3                     
   Lopinavir                             2449              1.9                      
  First-line ART regimen (NRTI)                                                     128 450
   Zidovudine                            92 542            72.1                     
   Stavudine                             9605              7.5                      
   Tenofovir                             26 303            20.5                     
  ART regimen switch                                                                129 946
   NRTI switch                           12 186            9.4                      
   NNRTI switch                          7085              5.5                      
   PI switch                             3832              3.0                      

ART, antiretroviral therapy; IQR, interquartile range.

^a^Reports on the 226 030 patients included in mortality rate analysis, unless otherwise noted below the heading the number of patients with complete data for that variable.

###### 

Predictors of mortality regression results and sensitivity analysis.^a,b,c^

                           Model 1: all patients   Model 2: including only patients in their first year of treatment   Model 3: excluding those initiating in 2012 and 2013                                    
  ------------------------ ----------------------- ------------------------------------------------------------------- ------------------------------------------------------ ---------------- --------------- ----------------
  Tenofovir                1                       1                                                                   1                                                      1                1               1
  Zidovudine               1.19^\*\*^              \[1.06, 1.34\]                                                      2.04^\*\*\*^                                           \[1.72, 2.42\]   1.06            \[0.95, 1.20\]
  Stavudine                4.91^\*\*\*^            \[4.30, 5.62\]                                                      6.47^\*\*\*^                                           \[5.33, 7.86\]   4.400^\*\*\*^   \[3.84, 5.04\]
  Nevirapine               1                       1                                                                   1                                                      1                1               1
  Efavirenz                1.12^\*\*^              \[1.03, 1.20\]                                                      0.88^\*^                                               \[0.79, 0.98\]   1.166^\*\*\*^   \[1.08, 1.26\]
  Lopinavir                0.94                    \[0.73, 1.22\]                                                      0.32^\*\*\*^                                           \[0.19, 0.54\]   0.99            \[0.77, 1.29\]
  Ever switched NRTI       0.26^\*\*\*^            \[0.23, 0.29\]                                                      0.15                                                   \[0.02, 1.01\]   0.26^\*\*\*^    \[0.23, 0.29\]
  Ever switched NNRTI      0.58^\*\*\*^            \[0.51, 0.66\]                                                      1                                                      \[1,1\]          0.57^\*\*\*^    \[0.50, 0.66\]
  Initiation year \>2008   0.75^\*\*\*^            \[0.68, 0.83\]                                                      0.63^\*\*\*^                                           \[0.53, 0.73\]   0.77^\*\*\*^    \[0.69, 0.85\]
  Female                   0.66^\*\*\*^            \[0.62, 0.71\]                                                      0.77^\*\*\*^                                           \[0.70, 0.84\]   0.68^\*\*\*^    \[0.64, 0.74\]
  Age \>40                 1.21^\*\*\*^            \[1.14, 1.28\]                                                      1.32^\*\*\*^                                           \[1.22, 1.44\]   1.19^\*\*\*^    \[1.12, 1.26\]
  Baseline CD4 \<100       1.92^\*\*\*^            \[1.82, 2.02\]                                                      2.57^\*\*\*^                                           \[2.38, 2.78\]   1.87^\*\*\*^    \[1.77, 1.97\]
  Follow-up month          0.92^\*\*\*^            \[0.92, 0.93\]                                                      0.95^\*\*\*^                                           \[0.94, 0.96\]   0.92^\*\*\*^    \[0.92, 0.93\]
  Sample size              996 770                                                                                     43 121                                                                  973 925         

CI, confidence interval; OR, odds ratio. Level of statistical significance: ^\*^0.1; ^\*\*^0.05; ^\*\*\*^0.001.

^a^Models are run with a cubic knot spline and with health district fixed effects (not reported here).

^b^Each variable is an indicator variable except for follow-up month, which is a continuous variable.

^c^Models are weighted to account for loss to follow-up.
